Global neoantigen cancer vaccine market to generate $1,826.1m revenue by 2030
Posted: 15 January 2020 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
A study suggests the global neoantigen cancer vaccine market will grow exponentially due to expected drug launches, new technology reducing costs and currently unmet needs of the market.
A new report suggests that the neoantigen cancer vaccine market will grow at a compound annual growth rate (CAGR) of 34.69 percent during the forecast period, 2023-2030.
…cost and time to manufacture have come down in the last four years”
The findings of the ResearchAndMarkets.com analysis indicate the neoantigen cancer vaccine market should generate $227.1 million revenue in 2023, greatly due to the expected launch of first neoantigen vaccine Tedopi in the market. The overall total revenue expected from the market by 2030 is $1,826.1 million.
The key market drivers listed in the report include Roche, Moderna Therapeutics/Merck joint venture and OSE Immunotherapeutics, among many others.
“The real issues with neovaccines are higher cost, turn-around times and limited efficacy. The cost and time to manufacture have come down in the last four years and as technology improves it will come down more,” reveals a ResearchAndMarkets.com expert, suggesting that this is why the market may continue such expansion.
Related topics
Anti-Cancer Therapeutics, Biopharmaceuticals, Drug Manufacturing, Drug Markets, Immunotherapy, Production, Vaccines
Related organisations
Merck, Moderna, OSE Immunotherapeutics, Research and Markets, Roche
